Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 10/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495610 | 0.96 | NR1I2 (0.69) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14342831 | 0.96 | NR1I2 (0.69) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13841880 | 0.95 | NR1I2 (0.67) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL54343 | 0.94 | NR1I2 (0.67) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4502638 | 0.93 | KCNH2 (0.76) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14343818 | 0.93 | NR1I2 (0.70) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13869505 | 0.93 | NR1I2 (0.70) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14438943 | 0.93 | NR1I2 (0.68) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13936763 | 0.92 | NR1I2 (0.82) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL12450618 | 0.91 | NR1I2 (0.66) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485633-B2 | RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease; (+/-)-8-Cyclohexyl-N-4-(morpholinosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485633-B2 | RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease; (+/-)-8-Cyclohexyl-N-4-(morpholinosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2008111978-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-7399758-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-15 | — | — | US | disclosed |
| US-7399758-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-15 | — | — | US | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| WO-2007033032-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | NR1I2 201/4885KCNH2 934/4885CYP3A4 41/4885 |
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | NR1I2 201/4885KCNH2 934/4885CYP3A4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.